Review

anxa1 fpr2 antagonist wrw4 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress anxa1 fpr2 antagonist wrw4
Anxa1 Fpr2 Antagonist Wrw4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anxa1/WRW4/pm42026088-413-13-19
Average 94 stars, based on 24 article reviews

anxa1 fpr2 antagonist wrw4 - by Bioz Stars, 2026-09

94/100 stars

Images

Injection:

Article Title: Annexin A1 mRNA-loaded liposomes alleviate acute pancreatitis by suppressing STING pathway and promoting efferocytosis in macrophages.
Article Snippet: Acute pancreatitis (AP) is associated with high mortality rates and is characterized by increased cell death of acinar cells, with the premature release and activation of digestive enzymes.. In its acute phase, AP is accompanied by increased efferocytosis, to clear phagocytic apoptotic cells; annexin A1 (Anxa1) is key to efferocytosis, but its role in AP is still unknown.. Here we show that Anxa1 deficiency abrogates the efferocytosis of pancreatic macrophages, resulting in the accumulation of apoptotic acinar cells and necrosis.

Incubation:

Article Title: Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
Article Snippet: After 48 h, positive clones were selected using 2.5 μg/mL puromycin (Beyotime, ST551-250 mg). .. Following a previously published method, HL60 cells were incubated with 500 nM ANXA1 (MCE, HY-P7512) for 6 h, or sorted Fpr1+ neutrophils were incubated with 500 nM Anxa1 (MCE, HY-P72078) for 6 h . Following the manufacturer’s instructions, Fpr1+ neutrophils treated with or without Anxa1 were stained with MitoTracker Red (Thermo Fisher, A66443) and Hoechst 33342 (Beyotime, R0305S-6) under light-protected conditions at 37 °C for 20 min. After staining, images were captured using a super-resolution microscope (Nikon, Tokyo, Japan) in SIM mode. ..

Article Title: Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils.
Article Snippet: After 48h, positive clones were selected using 2.5μg/mL puromycin (Beyotime, ST551-250mg). .. Following a previously published method, HL60 cells were incubated with 500 nM ANXA1 (MCE, HY-P7512) for 6 h, or sorted Fpr1+ neutrophils were incubated with 500 nM Anxa1 (MCE, HY-P72078) for 6 h31. .. Following the manufacturer’s instructions, Fpr1+ neutrophils treated with or without Anxa1 were stained with MitoTracker Red (Thermo Fisher, A66443) and Hoechst 33342 (Beyotime, R0305S-6) under light-protected conditions at 37 °C for 20min.

Staining:

Super-Resolution Microscopy:

Image Search Results

(A) Gene Set Enrichment Analysis (GSEA) comparing CD8⁺ naïve T cells from Elderly versus other groups of donors. Plots show significant enrichment of the Cellular Senescence (GO:0090398) and Senescence-Associated Secretory Phenotype (SASP; R-HSA-2559582) gene sets in the Elderly group. NES, normalized enrichment score. (B) Heatmap displaying the expression of senescence-associated signature genes in CD8⁺ naïve T cells across all donors. Each row is scaled using a Z-score. (C) Violin plot showing the normalized expression level of ANXA1 in CD8⁺ naïve T cells across the five age groups from scRNA-seq data. (D) Quantification of ANXA1 surface expression in CD8⁺ naïve T cells across the five age groups, as measured by flow cytometry. Each point represents an individual donor (Kid, n = 31; Young, n = 98; Middle-aged, n = 93; Pre-Elderly, n = 52; Elderly, n = 63). (E) Representative flowcytometry plots and summary quantification of total ANXA1 expression levels in CD8⁺ naïve T cells from human PBMCs (n = 5 per group). (F) Pathway enrichment analysis comparing human ANXA1⁺ versus ANXA1⁻ CD8⁺ naïve T cells from RNA-seq. The bubble plot shows key pathways significantly altered between the two subsets. Bubble size corresponds to the number of genes, and color indicates enrichment significance. (G) Representative immunofluorescence images for ANXA1 and p16 INK4a expression in human CD8⁺ naïve T cells. Scale bar, 10 µm. (H) Representative flow cytometry histogram and quantification p16 INK4a expression in human ANXA1⁺ versus ANXA1⁻ CD8⁺ naïve T cells (n = 5 per group). (I) Representative histogram of Cell Trace Violet (CTV) dye dilution in human ANXA1⁻ and ANXA1⁺ CD8⁺ naïve T cells after 72 hours of stimulation. Data are presented as mean ± SEM. P -value was determined by one-way ANOVA and two-tailed unpaired t-test.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Gene Set Enrichment Analysis (GSEA) comparing CD8⁺ naïve T cells from Elderly versus other groups of donors. Plots show significant enrichment of the Cellular Senescence (GO:0090398) and Senescence-Associated Secretory Phenotype (SASP; R-HSA-2559582) gene sets in the Elderly group. NES, normalized enrichment score. (B) Heatmap displaying the expression of senescence-associated signature genes in CD8⁺ naïve T cells across all donors. Each row is scaled using a Z-score. (C) Violin plot showing the normalized expression level of ANXA1 in CD8⁺ naïve T cells across the five age groups from scRNA-seq data. (D) Quantification of ANXA1 surface expression in CD8⁺ naïve T cells across the five age groups, as measured by flow cytometry. Each point represents an individual donor (Kid, n = 31; Young, n = 98; Middle-aged, n = 93; Pre-Elderly, n = 52; Elderly, n = 63). (E) Representative flowcytometry plots and summary quantification of total ANXA1 expression levels in CD8⁺ naïve T cells from human PBMCs (n = 5 per group). (F) Pathway enrichment analysis comparing human ANXA1⁺ versus ANXA1⁻ CD8⁺ naïve T cells from RNA-seq. The bubble plot shows key pathways significantly altered between the two subsets. Bubble size corresponds to the number of genes, and color indicates enrichment significance. (G) Representative immunofluorescence images for ANXA1 and p16 INK4a expression in human CD8⁺ naïve T cells. Scale bar, 10 µm. (H) Representative flow cytometry histogram and quantification p16 INK4a expression in human ANXA1⁺ versus ANXA1⁻ CD8⁺ naïve T cells (n = 5 per group). (I) Representative histogram of Cell Trace Violet (CTV) dye dilution in human ANXA1⁻ and ANXA1⁺ CD8⁺ naïve T cells after 72 hours of stimulation. Data are presented as mean ± SEM. P -value was determined by one-way ANOVA and two-tailed unpaired t-test.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: Expressing, Flow Cytometry, RNA Sequencing, Immunofluorescence, Two Tailed Test

(A) Representative flow cytometric analysis of CCL5 expression on CD8 + naïve T cells in samples of young (19-35 y) and old (>65 y) group (n= 5 per group). (B) Sub-clustering of CD8⁺ naïve T cells from the scRNA-seq dataset. UMAP projection showing distinct subclusters (C1-C6) identified within the CD8⁺ naïve T cell population. (C) Feature plot overlaying normalized ANXA1 expression onto the UMAP projection from ( B ), highlighting its specific enrichment in the C4 subcluster. (D) Scatter plots showing the correlation between the relative abundance of each subcluster (as a percentage of total CD8⁺ naïve T cells) and donor age. Lines represent linear regression fits; Pearson correlation coefficient (R) and P -values are indicated. ( E and F ) Violin plots ( E ) and heatmap ( F ) validating the naïve identity of both ANXA1 − and ANXA1⁺ CD8⁺ naïve T cells defined in human scRNA-seq data. Average expression of canonical lineage markers for naïve, memory, effector, and exhausted T cells is compared across three populations with CD8⁺ effector memory (Tem) cells as a non-naïve control. Expression values are scaled per row. (G) Representative immunofluorescence images and quantification of ANXA1 surface expression on mouse CD8⁺ naïve T cells from Young (8-week-old, n = 5) and Old (13-month-old, n = 5) mice. Scale bar, 5 µm. (H) Representative flow cytometry results and quantifications on the percentage of CD8 + naïve T cells and surface ANXA1 expression in young and old mice (n = 3 per group). Data in quantification plots are presented as mean ± SEM. Statistical significance was determined by one-way ANOVA and two-tailed unpaired t-test.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Representative flow cytometric analysis of CCL5 expression on CD8 + naïve T cells in samples of young (19-35 y) and old (>65 y) group (n= 5 per group). (B) Sub-clustering of CD8⁺ naïve T cells from the scRNA-seq dataset. UMAP projection showing distinct subclusters (C1-C6) identified within the CD8⁺ naïve T cell population. (C) Feature plot overlaying normalized ANXA1 expression onto the UMAP projection from ( B ), highlighting its specific enrichment in the C4 subcluster. (D) Scatter plots showing the correlation between the relative abundance of each subcluster (as a percentage of total CD8⁺ naïve T cells) and donor age. Lines represent linear regression fits; Pearson correlation coefficient (R) and P -values are indicated. ( E and F ) Violin plots ( E ) and heatmap ( F ) validating the naïve identity of both ANXA1 − and ANXA1⁺ CD8⁺ naïve T cells defined in human scRNA-seq data. Average expression of canonical lineage markers for naïve, memory, effector, and exhausted T cells is compared across three populations with CD8⁺ effector memory (Tem) cells as a non-naïve control. Expression values are scaled per row. (G) Representative immunofluorescence images and quantification of ANXA1 surface expression on mouse CD8⁺ naïve T cells from Young (8-week-old, n = 5) and Old (13-month-old, n = 5) mice. Scale bar, 5 µm. (H) Representative flow cytometry results and quantifications on the percentage of CD8 + naïve T cells and surface ANXA1 expression in young and old mice (n = 3 per group). Data in quantification plots are presented as mean ± SEM. Statistical significance was determined by one-way ANOVA and two-tailed unpaired t-test.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: Expressing, Control, Immunofluorescence, Flow Cytometry, Two Tailed Test

(A) Heatmap of DEGs from RNA-seq of resting WT and Anxa1 KO CD8⁺ naïve T cells. (B) GO enrichment bubble plot of pathways upregulated in Anxa1 KO versus WT CD8⁺ naïve T cells at basal state.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Heatmap of DEGs from RNA-seq of resting WT and Anxa1 KO CD8⁺ naïve T cells. (B) GO enrichment bubble plot of pathways upregulated in Anxa1 KO versus WT CD8⁺ naïve T cells at basal state.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: RNA Sequencing

(A) Heatmap of DEGs in activated CD8⁺ naïve T cells from WT and Anxa1 KO mice. Cells were stimulated with anti-CD3/CD28 antibodies for 12 hours prior to RNA-seq. Each row is scaled using a Z-score. (B) GO enrichment of pathways upregulated in activated Anxa1 KO CD8⁺ naïve T cells compared with WT. ( C and D ) Representative flow cytometry histograms and quantification of activation markers CD69 ( C ) and CD25 ( D ) on WT and Anxa1 KO CD8⁺ naïve T cells 12 hours post-stimulation (n = 6 per group). (E) Representative flow cytometry plots and quantification of IFNγ-producing cells within WT and Anxa1 KO CD8⁺ T cells after stimulation (n = 6 per group). (F) Representative flow cytometry plots and quantification of the degranulation marker CD107a on WT and Anxa1 KO CD8⁺ T cells after stimulation (n = 6 per group). (G) Schematic of the B16-F10 inoculation model. C57BL/6 mice were inoculated subcutaneously with B16-F10 melanoma cells, followed by adoptive transfer of CD8⁺ T cells isolated from either WT or Anxa1 KO mice. (H) Representative image and quantification of excised tumors at day 20 post-inoculation. (n = 6 per group). Data in quantification plots are presented as mean ± SEM. P-values were determined by two-tailed unpaired t-test.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Heatmap of DEGs in activated CD8⁺ naïve T cells from WT and Anxa1 KO mice. Cells were stimulated with anti-CD3/CD28 antibodies for 12 hours prior to RNA-seq. Each row is scaled using a Z-score. (B) GO enrichment of pathways upregulated in activated Anxa1 KO CD8⁺ naïve T cells compared with WT. ( C and D ) Representative flow cytometry histograms and quantification of activation markers CD69 ( C ) and CD25 ( D ) on WT and Anxa1 KO CD8⁺ naïve T cells 12 hours post-stimulation (n = 6 per group). (E) Representative flow cytometry plots and quantification of IFNγ-producing cells within WT and Anxa1 KO CD8⁺ T cells after stimulation (n = 6 per group). (F) Representative flow cytometry plots and quantification of the degranulation marker CD107a on WT and Anxa1 KO CD8⁺ T cells after stimulation (n = 6 per group). (G) Schematic of the B16-F10 inoculation model. C57BL/6 mice were inoculated subcutaneously with B16-F10 melanoma cells, followed by adoptive transfer of CD8⁺ T cells isolated from either WT or Anxa1 KO mice. (H) Representative image and quantification of excised tumors at day 20 post-inoculation. (n = 6 per group). Data in quantification plots are presented as mean ± SEM. P-values were determined by two-tailed unpaired t-test.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: RNA Sequencing, Flow Cytometry, Activation Assay, Marker, Adoptive Transfer Assay, Isolation, Two Tailed Test

(A) Representative flow cytometry histograms and quantifications of CTV-staining, CD69 and CD25 expression of ANXA1 − CD8 + naïve T cells from young and aged mice (n = 3 per group). (B) Representative flow cytometry results and quantifications of Tc1 differentiation of ANXA1 − CD8 + naïve T cells from young and aged mice. (C) Representative images and quantification from a transwell invasion assay showing that both young and old mouse ANXA1⁻ T cells, but not ANXA1⁺ T cells (n = 5 per group), significantly inhibit the invasion of U-2 OS tumor cells, with arrows indicate tumor cells passed the transwell membrane. Data are presented as mean ± SEM. P -values were determined by one-way ANOVA and two-tailed unpaired t-test.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Representative flow cytometry histograms and quantifications of CTV-staining, CD69 and CD25 expression of ANXA1 − CD8 + naïve T cells from young and aged mice (n = 3 per group). (B) Representative flow cytometry results and quantifications of Tc1 differentiation of ANXA1 − CD8 + naïve T cells from young and aged mice. (C) Representative images and quantification from a transwell invasion assay showing that both young and old mouse ANXA1⁻ T cells, but not ANXA1⁺ T cells (n = 5 per group), significantly inhibit the invasion of U-2 OS tumor cells, with arrows indicate tumor cells passed the transwell membrane. Data are presented as mean ± SEM. P -values were determined by one-way ANOVA and two-tailed unpaired t-test.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: Flow Cytometry, Staining, Expressing, Transwell Invasion Assay, Membrane, Two Tailed Test

(A) Schematic of the co-culture experiment using fibroblasts engineered to express p16 INK4a -GFP as a model of senescent cells. Human ANXA1 − or ANXA1 + CD8 + naïve T cells using FACS were co-cultured with fibroblasts for live imaging. (B) Representative stills from live-cell imaging showing the targeting and clearance of p16 INK4a -GFP⁺ senescent cells by ANXA1 − or ANXA1 + CD8 + naïve T cells 6 hours post-culture. (C) Representative immunofluorescence images and quantification of p53- and γH2AX- expressing fibroblasts after co-culture in UV-B induced senescence model (n = 6 per group), corresponding with . (D) Schematic of an Etoposide-induced senescence model. (E) Representative immunofluorescence images and quantification showing a significant reduction of p16 INK4a -positive senescent fibroblasts after co-culture with ANXA1⁻ T cells, but not with ANXA1⁺ T cells (n = 5 per group). Scale bar, 10 µm. (F) Representative immunofluorescence images and quantification of GZMB-secreting cells from different T cell groups after co-culture in (E) (n = 5 per group). Scale bar, 10 µm. Data are presented as mean ± SEM. P -values were determined by one-way ANOVA and two-tailed unpaired t-test.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Schematic of the co-culture experiment using fibroblasts engineered to express p16 INK4a -GFP as a model of senescent cells. Human ANXA1 − or ANXA1 + CD8 + naïve T cells using FACS were co-cultured with fibroblasts for live imaging. (B) Representative stills from live-cell imaging showing the targeting and clearance of p16 INK4a -GFP⁺ senescent cells by ANXA1 − or ANXA1 + CD8 + naïve T cells 6 hours post-culture. (C) Representative immunofluorescence images and quantification of p53- and γH2AX- expressing fibroblasts after co-culture in UV-B induced senescence model (n = 6 per group), corresponding with . (D) Schematic of an Etoposide-induced senescence model. (E) Representative immunofluorescence images and quantification showing a significant reduction of p16 INK4a -positive senescent fibroblasts after co-culture with ANXA1⁻ T cells, but not with ANXA1⁺ T cells (n = 5 per group). Scale bar, 10 µm. (F) Representative immunofluorescence images and quantification of GZMB-secreting cells from different T cell groups after co-culture in (E) (n = 5 per group). Scale bar, 10 µm. Data are presented as mean ± SEM. P -values were determined by one-way ANOVA and two-tailed unpaired t-test.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: Co-Culture Assay, Cell Culture, Imaging, Live Cell Imaging, Immunofluorescence, Expressing, Two Tailed Test

(A) Representative stills from live-cell imaging of p16 INK4a -GFP⁺ senescent fibroblasts (green), normal fibroblasts (grey) co-cultured with sorted surface ANXA1⁻ CD8⁺ naïve T cells (magenta), with arrows indicate interaction spots. (B) Schematic diagram of the in vitro UV-B induced senescence co-culture system. Mouse fibroblasts (mFib) were induced into senescence by UV-B radiation and then co-cultured for 5 days with different subsets of sorted CD8⁺ naïve T cells. (C) Representative immunofluorescence images and quantification of p21-positive fibroblasts after co-culture with the indicated T cell subsets (n = 6 per group). Scale bar, 10 µm. (D) Western blot analysis of p16 INK4a protein levels in senescent fibroblasts following co-culture. (E) Schematic of the doxorubicin (Doxo)-induced systemic senescence model. Mice received a single intravenous ( i.v. ) injection of ANXA1⁻ CD8⁺ naïve T cells prior to treatment with Doxo. (F) Rotarod test quantification showing motor coordination and endurance in mice (n = 5 per group). (G) Weight loss of mice in different groups (n = 5 per group) in Doxo-induced senescence model. Initial body weight was normalized to 100%. (H) Representative images and quantifications of p16 INK4a and γH2AX in the heart and kidney from Doxo-treated mice (n = 5 per group). Scale bar, 5 µm. Data in quantification plots are presented as mean ± SEM. P-values were determined by one-way ANOVA and two-tailed unpaired t-test.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Representative stills from live-cell imaging of p16 INK4a -GFP⁺ senescent fibroblasts (green), normal fibroblasts (grey) co-cultured with sorted surface ANXA1⁻ CD8⁺ naïve T cells (magenta), with arrows indicate interaction spots. (B) Schematic diagram of the in vitro UV-B induced senescence co-culture system. Mouse fibroblasts (mFib) were induced into senescence by UV-B radiation and then co-cultured for 5 days with different subsets of sorted CD8⁺ naïve T cells. (C) Representative immunofluorescence images and quantification of p21-positive fibroblasts after co-culture with the indicated T cell subsets (n = 6 per group). Scale bar, 10 µm. (D) Western blot analysis of p16 INK4a protein levels in senescent fibroblasts following co-culture. (E) Schematic of the doxorubicin (Doxo)-induced systemic senescence model. Mice received a single intravenous ( i.v. ) injection of ANXA1⁻ CD8⁺ naïve T cells prior to treatment with Doxo. (F) Rotarod test quantification showing motor coordination and endurance in mice (n = 5 per group). (G) Weight loss of mice in different groups (n = 5 per group) in Doxo-induced senescence model. Initial body weight was normalized to 100%. (H) Representative images and quantifications of p16 INK4a and γH2AX in the heart and kidney from Doxo-treated mice (n = 5 per group). Scale bar, 5 µm. Data in quantification plots are presented as mean ± SEM. P-values were determined by one-way ANOVA and two-tailed unpaired t-test.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: Live Cell Imaging, Cell Culture, In Vitro, Co-Culture Assay, Immunofluorescence, Western Blot, Injection, Two Tailed Test

(A) Schematic of the long-term therapeutic study design. Old (13-month-old) mice received monthly intravenous ( i.v. ) transfers of Anxa1⁻ CD8⁺ naïve T cells (Old-Treated group) or a vehicle control (Old-Ctrl group) for the duration of the study. (B) Kaplan-Meier survival curves for all mice with sexes combined. Statistical significance was determined by the Log-rank test. Median survival is indicated by dashed lines. (C) Representative photographs of mice at 30 months of age, highlighting the improved physical condition in the treated mouse. (D) Single-cell t-SNE projections of total CD45⁺ immune cells from the bone marrow of Old-Ctrl and Old-Treated mice (n = 2 per group). Left: Integrated UMAP colored by major cell lineages. Right: The same UMAP split by treatment group to visualize compositional shifts. (E) Box plots show the relative abundance of Inflammatory, Lymphoid, and Myeloid cell clusters as a percentage of total CD45⁺ cells between the two groups. (F) Violin plots comparing the senescence score, calculated per cell, between the Old-Ctrl and Old-Treated groups. The gene list for this score is provided in the Methods section. Statistical significance was determined by two-tailed unpaired t-test. (G) Density plot comparing the “Aging score” for all CD8⁺ T cells from the three experimental groups. The gene list for this score is provided in the Methods section. (H) GSEA enrichment analysis comparing Old-Treated versus Old-Ctrl CD8⁺ T cells. Bar plot shows NES for selected Hallmark gene sets. Purple bars indicate pathways enriched in Old-Ctrl, while orange bars indicate pathways enriched in Old-Treated cells.

Journal: bioRxiv

Article Title: Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through Senolysis

doi: 10.64898/2026.02.21.707223

Figure Lengend Snippet: (A) Schematic of the long-term therapeutic study design. Old (13-month-old) mice received monthly intravenous ( i.v. ) transfers of Anxa1⁻ CD8⁺ naïve T cells (Old-Treated group) or a vehicle control (Old-Ctrl group) for the duration of the study. (B) Kaplan-Meier survival curves for all mice with sexes combined. Statistical significance was determined by the Log-rank test. Median survival is indicated by dashed lines. (C) Representative photographs of mice at 30 months of age, highlighting the improved physical condition in the treated mouse. (D) Single-cell t-SNE projections of total CD45⁺ immune cells from the bone marrow of Old-Ctrl and Old-Treated mice (n = 2 per group). Left: Integrated UMAP colored by major cell lineages. Right: The same UMAP split by treatment group to visualize compositional shifts. (E) Box plots show the relative abundance of Inflammatory, Lymphoid, and Myeloid cell clusters as a percentage of total CD45⁺ cells between the two groups. (F) Violin plots comparing the senescence score, calculated per cell, between the Old-Ctrl and Old-Treated groups. The gene list for this score is provided in the Methods section. Statistical significance was determined by two-tailed unpaired t-test. (G) Density plot comparing the “Aging score” for all CD8⁺ T cells from the three experimental groups. The gene list for this score is provided in the Methods section. (H) GSEA enrichment analysis comparing Old-Treated versus Old-Ctrl CD8⁺ T cells. Bar plot shows NES for selected Hallmark gene sets. Purple bars indicate pathways enriched in Old-Ctrl, while orange bars indicate pathways enriched in Old-Treated cells.

Article Snippet: C57BL/6 CD45.2 mice, C57BL/6 CD45.1 mice, Anxa1 KO mice were purchased from Suzhou Cyagen Biotechnology Co., Ltd. affiliated to Cyagen US Inc.

Techniques: Control, Single Cell, Two Tailed Test

(A) Western blot validating ANXA1 overexpression in PK15 and IPEC-J2 cells using mouse anti-ANXA1 antibody. (B) RT-qPCR analysis of PAstV infection (MOI = 0.01) at 24 h in ANXA1-overexpressing PK15 and IPEC-J2 cells. (C) Schematic design of CRISPR-resistant ANXA1 (pANXA1). (D) Western blot confirming ANXA1 restoration in PK15-ANXA1KO after PAstV infection. (E) RT-qPCR analysis of PAstV infection (MOI = 0.01) at 24 h in ANXA1-rescued PK15 cells. (F) RT-qPCR analysis of PAstV infection (MOI = 0.01) at 24 h in ANXA1 polyclonal KO IPEC-J2 cells. (G) Immunofluorescence detection of virus replication in PK15-WT and PK15-ANXA1 KO cells. (H) RT-qPCR analysis of virus replication (MOI = 0.1) in PK15-ANXA1 KO cells at 24 h post-infection. (I, J) Western blot (I) and RT-qPCR (J) analysis of ANXA1 expression in PK15 cells infected with PAstV (MOI = 1). Data represent mean ± SD (n = 3). Statistical significance by unpaired two-tailed Student’s t-test and Two-way ANOVA. (ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001).

Journal: PLOS Pathogens

Article Title: Genome-wide CRISPR screening identifies Annexin A1 as a facilitator of porcine astrovirus entry

doi: 10.1371/journal.ppat.1013943

Figure Lengend Snippet: (A) Western blot validating ANXA1 overexpression in PK15 and IPEC-J2 cells using mouse anti-ANXA1 antibody. (B) RT-qPCR analysis of PAstV infection (MOI = 0.01) at 24 h in ANXA1-overexpressing PK15 and IPEC-J2 cells. (C) Schematic design of CRISPR-resistant ANXA1 (pANXA1). (D) Western blot confirming ANXA1 restoration in PK15-ANXA1KO after PAstV infection. (E) RT-qPCR analysis of PAstV infection (MOI = 0.01) at 24 h in ANXA1-rescued PK15 cells. (F) RT-qPCR analysis of PAstV infection (MOI = 0.01) at 24 h in ANXA1 polyclonal KO IPEC-J2 cells. (G) Immunofluorescence detection of virus replication in PK15-WT and PK15-ANXA1 KO cells. (H) RT-qPCR analysis of virus replication (MOI = 0.1) in PK15-ANXA1 KO cells at 24 h post-infection. (I, J) Western blot (I) and RT-qPCR (J) analysis of ANXA1 expression in PK15 cells infected with PAstV (MOI = 1). Data represent mean ± SD (n = 3). Statistical significance by unpaired two-tailed Student’s t-test and Two-way ANOVA. (ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001).

Article Snippet: Primary antibodies used included anti-ANXA1 (21990–1-AP), anti-RIG-I (67556–1-Ig), anti-IRF3 (11312–1-AP), anti-phospho-IRF3 (29528–1-AP), anti-caspase 3/P17/P19 (82202–1-RR), anti-Flag (66008–4-Ig), anti-beta-tubulin (10094–1-AP), and anti-HA-HRP (HRP-81290) were purchased from Proteintech, China.

Techniques: Western Blot, Over Expression, Quantitative RT-PCR, Infection, CRISPR, Immunofluorescence, Virus, Expressing, Two Tailed Test

Spatial transcriptome analysis and IHC staining of candidate markers. A, Representative image obtained with the GeoMx DSP system. ROIs were defined within the tumor area. Green: pan-cytokeratin, epithelial cell marker; red: CD68, macrophage marker; yellow: CD45, pan-leukocyte cell marker; and blue: SYTO13, nuclear DNA marker. B, Volcano plot of the RNA expression that is differentially expressed by early resistance and responder groups in the pan-cytokeratin positive areas of ROIs. C–E, Representative images of ANXA1 ( C ), LCN2 ( D ), and CLDN4 (E ) IHC staining in each patient. Scale bars, 100 μm.

Journal: Cancer Research Communications

Article Title: Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study

doi: 10.1158/2767-9764.CRC-25-0545

Figure Lengend Snippet: Spatial transcriptome analysis and IHC staining of candidate markers. A, Representative image obtained with the GeoMx DSP system. ROIs were defined within the tumor area. Green: pan-cytokeratin, epithelial cell marker; red: CD68, macrophage marker; yellow: CD45, pan-leukocyte cell marker; and blue: SYTO13, nuclear DNA marker. B, Volcano plot of the RNA expression that is differentially expressed by early resistance and responder groups in the pan-cytokeratin positive areas of ROIs. C–E, Representative images of ANXA1 ( C ), LCN2 ( D ), and CLDN4 (E ) IHC staining in each patient. Scale bars, 100 μm.

Article Snippet: The sections were incubated with anti–annexin A1 (ANXA1) antibody (Cell Signaling Technology, D5V2T, RRID: AB_2799031; 1:400), anti–claudin 4 (CLDN4) antibody (Abcam, EPRR17575, RRID: AB_2732879; 1:4,000), anti–interleukin 6 (IL-6) antibody (Abcam, ab6672, RRID: AB_2127460; 1:200), phospho-STAT3 (Cell Signaling Technology, D3A7, RRID: AB_2491009; 1:200), and anti–lipocalin 2 (LCN2) antibody (Cell Signaling Technology, D4M8L, RRID: AB_2799257; 1:3,000) overnight at 4°C.

Techniques: Immunohistochemistry, Marker, RNA Expression

Effects of IL-6 and ANXA1 on alectinib sensitivity. A, WB analysis of ANXA1, LCN2, and CLDN4 in H3122, ABC-14, ABC-17, ABC-19, and ABC-23 cells. Data are representative of three independent experiments with similar results. B, WB analysis of ANXA1, STAT3, and phospho-STAT3 (pSTAT3) in H3122 cells treated with varying concentrations of IL-6 for 24 hours. Data are representative of three independent experiments with similar results. C, Cell proliferation assays at increasing concentrations with or without IL-6 (20 ng/mL) in H3122 cells treated with alectinib for 72 hours. Data are presented as the mean ± standard error ( n = 9 per group). *, P < 0.05, Student t test. D, IC 50 values of alectinib in H3122 cells with or without IL-6 treatment (20 ng/mL). Data are presented as the mean ± standard error ( n = 9 per group). *, P < 0.05, Student t test. E, WB analysis of ANXA1 expression in ABC-14 cells transfected with negative control siRNA or two different siRNAs targeting ANXA1 (siANXA1 #1, #2). Data are representative of three independent experiments with similar results. F, Cell proliferation assays in ABC-14 cells transfected with negative control siRNA (nega_si) or different siRNAs targeting ANXA1 [siANXA1 #1 (si#1), #2 (si#2)] treated with alectinib (Alec; 0.1 μmol/L) for 72 hours. n = 5 per group. Error bars represent the standard error. *, P < 0.05; ***, P < 0.001, Student t test comparing each siANXA1 group (Alec + si#1 or #2) with the negative control group (Alec + nega_si).

Journal: Cancer Research Communications

Article Title: Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study

doi: 10.1158/2767-9764.CRC-25-0545

Figure Lengend Snippet: Effects of IL-6 and ANXA1 on alectinib sensitivity. A, WB analysis of ANXA1, LCN2, and CLDN4 in H3122, ABC-14, ABC-17, ABC-19, and ABC-23 cells. Data are representative of three independent experiments with similar results. B, WB analysis of ANXA1, STAT3, and phospho-STAT3 (pSTAT3) in H3122 cells treated with varying concentrations of IL-6 for 24 hours. Data are representative of three independent experiments with similar results. C, Cell proliferation assays at increasing concentrations with or without IL-6 (20 ng/mL) in H3122 cells treated with alectinib for 72 hours. Data are presented as the mean ± standard error ( n = 9 per group). *, P < 0.05, Student t test. D, IC 50 values of alectinib in H3122 cells with or without IL-6 treatment (20 ng/mL). Data are presented as the mean ± standard error ( n = 9 per group). *, P < 0.05, Student t test. E, WB analysis of ANXA1 expression in ABC-14 cells transfected with negative control siRNA or two different siRNAs targeting ANXA1 (siANXA1 #1, #2). Data are representative of three independent experiments with similar results. F, Cell proliferation assays in ABC-14 cells transfected with negative control siRNA (nega_si) or different siRNAs targeting ANXA1 [siANXA1 #1 (si#1), #2 (si#2)] treated with alectinib (Alec; 0.1 μmol/L) for 72 hours. n = 5 per group. Error bars represent the standard error. *, P < 0.05; ***, P < 0.001, Student t test comparing each siANXA1 group (Alec + si#1 or #2) with the negative control group (Alec + nega_si).

Techniques: Expressing, Transfection, Negative Control

Journal: Cancer Research Communications

Article Title: Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study

doi: 10.1158/2767-9764.CRC-25-0545

Article Snippet: Primary antibodies for WB analysis against ANXA1 (D5V2T; 1:1,000), LCN2 (D4M8L; 1:1,000), STAT3 (79D7, RRID: AB_331269; 1:2,000), phospho-STAT3 (D3A7; 1:2,000), and GAPDH (14C10, RRID: AB_561053; 1:5,000) were purchased from Cell Signaling Technology, whereas primary antibodies against CLDN4 (EPRR17575; 1:1,000) were purchased from Abcam.

Techniques: Immunohistochemistry, Marker, RNA Expression

Journal: Cancer Research Communications

Article Title: Clinical Characteristics and Spatial Transcriptome Analysis of Non–Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study

doi: 10.1158/2767-9764.CRC-25-0545

Techniques: Expressing, Transfection, Negative Control

Review

anxa1 fpr2 antagonist wrw4 (MedChemExpress)

Structured Review

Images

Related Articles

Injection:

Incubation:

Staining:

Super-Resolution Microscopy:

Similar Products

Image Search Results